{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:20:43Z","timestamp":1790911243129,"version":"4.1.0"},"reference-count":103,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2018,11,6]],"date-time":"2018-11-06T00:00:00Z","timestamp":1541462400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["836031008"],"award-info":[{"award-number":["836031008"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Zorgverzekeraars Nederland"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1007\/s00467-018-4091-3","type":"journal-article","created":{"date-parts":[[2018,11,6]],"date-time":"2018-11-06T07:30:47Z","timestamp":1541489447000},"page":"2261-2277","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":97,"title":["Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use"],"prefix":"10.1007","volume":"34","author":[{"given":"Kioa L.","family":"Wijnsma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Duineveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack F. M.","family":"Wetzels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1990-1189","authenticated-orcid":false,"given":"Nicole C. A. J.","family":"van de Kar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,6]]},"reference":[{"key":"4091_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00467-015-3076-8","volume":"31","author":"C Loirat","year":"2016","unstructured":"Loirat C, Fakhouri F, Ariceta G, Besbas N, Bitzan M, Bjerre A, Coppo R, Emma F, Johnson S, Karpman D, Landau D, Langman CB, Lapeyraque AL, Licht C, Nester C, Pecoraro C, Riedl M, van de Kar NC, Van de Walle J, Vivarelli M, Fremeaux-Bacchi V (2016) An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol 31:15\u201339. \n                    https:\/\/doi.org\/10.1007\/s00467-015-3076-8","journal-title":"Pediatr Nephrol"},{"key":"4091_CR2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.molimm.2015.03.246","volume":"67","author":"CM Nester","year":"2015","unstructured":"Nester CM, Barbour T, de Cordoba SR, Dragon-Durey MA, Fremeaux-Bacchi V, Goodship TH, Kavanagh D, Noris M, Pickering M, Sanchez-Corral P, Skerka C, Zipfel P, Smith RJ (2015) Atypical aHUS: state of the art. Mol Immunol 67:31\u201342. \n                    https:\/\/doi.org\/10.1016\/j.molimm.2015.03.246","journal-title":"Mol Immunol"},{"key":"4091_CR3","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S0140-6736(17)30062-4","volume":"390","author":"F Fakhouri","year":"2017","unstructured":"Fakhouri F, Zuber J, Fremeaux-Bacchi V, Loirat C (2017) Haemolytic uraemic syndrome. Lancet 390:681\u2013696. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(17)30062-4","journal-title":"Lancet"},{"key":"4091_CR4","doi-asserted-by":"publisher","first-page":"554","DOI":"10.2215\/CJN.04760512","volume":"8","author":"V Fremeaux-Bacchi","year":"2013","unstructured":"Fremeaux-Bacchi V, Fakhouri F, Garnier A, Bienaime F, Dragon-Durey MA, Ngo S, Moulin B, Servais A, Provot F, Rostaing L, Burtey S, Niaudet P, Deschenes G, Lebranchu Y, Zuber J, Loirat C (2013) Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol 8:554\u2013562. \n                    https:\/\/doi.org\/10.2215\/CJN.04760512","journal-title":"Clin J Am Soc Nephrol"},{"key":"4091_CR5","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.2215\/CJN.02210310","volume":"5","author":"M Noris","year":"2010","unstructured":"Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, Daina E, Fenili C, Castelletti F, Sorosina A, Piras R, Donadelli R, Maranta R, van der Meer I, Conway EM, Zipfel PF, Goodship TH, Remuzzi G (2010) Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 5:1844\u20131859. \n                    https:\/\/doi.org\/10.2215\/CJN.02210310","journal-title":"Clin J Am Soc Nephrol"},{"issue":"Suppl 4","key":"4091_CR6","doi-asserted-by":"publisher","first-page":"iv131","DOI":"10.1093\/ndt\/gfu235","volume":"29","author":"JC Verhave","year":"2014","unstructured":"Verhave JC, Wetzels JF, van de Kar NC (2014) Novel aspects of atypical haemolytic uraemic syndrome and the role of eculizumab. Nephrol Dial Transplant 29(Suppl 4):iv131\u2013iv141. \n                    https:\/\/doi.org\/10.1093\/ndt\/gfu235","journal-title":"Nephrol Dial Transplant"},{"key":"4091_CR7","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1056\/NEJMra0902814","volume":"361","author":"M Noris","year":"2009","unstructured":"Noris M, Remuzzi G (2009) Atypical hemolytic-uremic syndrome. N Engl J Med 361:1676\u20131687. \n                    https:\/\/doi.org\/10.1056\/NEJMra0902814","journal-title":"N Engl J Med"},{"key":"4091_CR8","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1111\/ajt.12077","volume":"13","author":"M Quintrec Le","year":"2013","unstructured":"Le Quintrec M, Zuber J, Moulin B, Kamar N, Jablonski M, Lionet A, Chatelet V, Mousson C, Mourad G, Bridoux F, Cassuto E, Loirat C, Rondeau E, Delahousse M, Fremeaux-Bacchi V (2013) Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome. Am J Transplant 13:663\u2013675. \n                    https:\/\/doi.org\/10.1111\/ajt.12077","journal-title":"Am J Transplant"},{"key":"4091_CR9","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s00467-008-0964-1","volume":"24","author":"G Ariceta","year":"2009","unstructured":"Ariceta G, Besbas N, Johnson S, Karpman D, Landau D, Licht C, Loirat C, Pecoraro C, Taylor CM, Van de Kar N, Vandewalle J, Zimmerhackl LB, European Paediatric Study Group for HUS (2009) Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatr Nephrol 24:687\u2013696. \n                    https:\/\/doi.org\/10.1007\/s00467-008-0964-1","journal-title":"Pediatr Nephrol"},{"key":"4091_CR10","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1007\/s00467-014-2817-4","volume":"29","author":"S Johnson","year":"2014","unstructured":"Johnson S, Stojanovic J, Ariceta G, Bitzan M, Besbas N, Frieling M, Karpman D, Landau D, Langman C, Licht C, Pecoraro C, Riedl M, Siomou E, van de Kar N, Walle JV, Loirat C, Taylor CM (2014) An audit analysis of a guideline for the investigation and initial therapy of diarrhea negative (atypical) hemolytic uremic syndrome. Pediatr Nephrol 29:1967\u20131978. \n                    https:\/\/doi.org\/10.1007\/s00467-014-2817-4","journal-title":"Pediatr Nephrol"},{"key":"4091_CR11","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1111\/j.1537-2995.2007.01405.x","volume":"47","author":"B Michon","year":"2007","unstructured":"Michon B, Moghrabi A, Winikoff R, Barrette S, Bernstein ML, Champagne J, David M, Duval M, Hume HA, Robitaille N, Belisle A, Champagne MA (2007) Complications of apheresis in children. Transfusion (Paris) 47:1837\u20131842. \n                    https:\/\/doi.org\/10.1111\/j.1537-2995.2007.01405.x","journal-title":"Transfusion (Paris)"},{"key":"4091_CR12","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","volume":"368","author":"CM Legendre","year":"2013","unstructured":"Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, Nurnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T, Loirat C (2013) Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 368:2169\u20132181. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1208981","journal-title":"N Engl J Med"},{"key":"4091_CR13","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/ki.2014.423","volume":"87","author":"C Licht","year":"2015","unstructured":"Licht C, Greenbaum LA, Muus P, Babu S, Bedrosian CL, Cohen DJ, Delmas Y, Douglas K, Furman RR, Gaber OA, Goodship T, Herthelius M, Hourmant M, Legendre CM, Remuzzi G, Sheerin N, Trivelli A, Loirat C (2015) Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int 87:1061\u20131073. \n                    https:\/\/doi.org\/10.1038\/ki.2014.423","journal-title":"Kidney Int"},{"key":"4091_CR14","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.kint.2015.11.026","volume":"89","author":"LA Greenbaum","year":"2016","unstructured":"Greenbaum LA, Fila M, Ardissino G, Al-Akash SI, Evans J, Henning P, Lieberman KV, Maringhini S, Pape L, Rees L, van de Kar NC, Vande Walle J, Ogawa M, Bedrosian CL, Licht C (2016) Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int 89:701\u2013711. \n                    https:\/\/doi.org\/10.1016\/j.kint.2015.11.026","journal-title":"Kidney Int"},{"key":"4091_CR15","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.kint.2016.10.005","volume":"91","author":"TH Goodship","year":"2017","unstructured":"Goodship TH, Cook HT, Fakhouri F, Fervenza FC, Fremeaux-Bacchi V, Kavanagh D, Nester CM, Noris M, Pickering MC, Rodriguez de Cordoba S, Roumenina LT, Sethi S, Smith RJ, Conference P (2017) Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a \u201ckidney disease: improving global outcomes\u201d (KDIGO) controversies conference. Kidney Int 91:539\u2013551. \n                    https:\/\/doi.org\/10.1016\/j.kint.2016.10.005","journal-title":"Kidney Int"},{"key":"4091_CR16","unstructured":"Food and drug administration (2011) Approval Package for Solirit"},{"key":"4091_CR17","unstructured":"European Medicines Agency (2017) Summary of product characteristics"},{"key":"4091_CR18","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1007\/s00467-012-2131-y","volume":"27","author":"LM Geerdink","year":"2012","unstructured":"Geerdink LM, Westra D, van Wijk JA, Dorresteijn EM, Lilien MR, Davin JC, Komhoff M, Van Hoeck K, van der Vlugt A, van den Heuvel LP, van de Kar NC (2012) Atypical hemolytic uremic syndrome in children: complement mutations and clinical characteristics. Pediatr Nephrol 27:1283\u20131291. \n                    https:\/\/doi.org\/10.1007\/s00467-012-2131-y","journal-title":"Pediatr Nephrol"},{"key":"4091_CR19","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1182\/blood-2005-10-007252","volume":"108","author":"J Caprioli","year":"2006","unstructured":"Caprioli J, Noris M, Brioschi S, Pianetti G, Castelletti F, Bettinaglio P, Mele C, Bresin E, Cassis L, Gamba S, Porrati F, Bucchioni S, Monteferrante G, Fang CJ, Liszewski MK, Kavanagh D, Atkinson JP, Remuzzi G, International Registry of R, Familial HT (2006) Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 108:1267\u20131279. \n                    https:\/\/doi.org\/10.1182\/blood-2005-10-007252","journal-title":"Blood"},{"key":"4091_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0177894","volume":"12","author":"M Jamme","year":"2017","unstructured":"Jamme M, Raimbourg Q, Chauveau D, Seguin A, Presne C, Perez P, Gobert P, Wynckel A, Provot F, Delmas Y, Mousson C, Servais A, Vrigneaud L, Veyradier A, Rondeau E, Coppo P, French Thrombotic Microangiopathies Reference C (2017) Predictive features of chronic kidney disease in atypical haemolytic uremic syndrome. PLoS One 12:e0177894. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0177894","journal-title":"PLoS One"},{"key":"4091_CR21","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/qco.0000000000000279","volume":"29","author":"E Benamu","year":"2016","unstructured":"Benamu E, Montoya JG (2016) Infections associated with the use of eculizumab: recommendations for prevention and prophylaxis. Curr Opin Infect Dis 29:319\u2013329. \n                    https:\/\/doi.org\/10.1097\/qco.0000000000000279","journal-title":"Curr Opin Infect Dis"},{"key":"4091_CR22","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1182\/blood-2017-05-781450","volume":"130","author":"M Konar","year":"2017","unstructured":"Konar M, Granoff DM (2017) Eculizumab treatment and impaired opsonophagocytic killing of meningococci by whole blood from immunized adults. Blood 130:891\u2013899. \n                    https:\/\/doi.org\/10.1182\/blood-2017-05-781450","journal-title":"Blood"},{"key":"4091_CR23","doi-asserted-by":"publisher","first-page":"e1506","DOI":"10.1542\/peds.2014-3503","volume":"135","author":"N Cullinan","year":"2015","unstructured":"Cullinan N, Gorman KM, Riordan M, Waldron M, Goodship TH, Awan A (2015) Case report: benefits and challenges of long-term eculizumab in atypical hemolytic uremic syndrome. Pediatrics 135:e1506\u2013e1509. \n                    https:\/\/doi.org\/10.1542\/peds.2014-3503","journal-title":"Pediatrics"},{"key":"4091_CR24","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1111\/ajt.12032","volume":"13","author":"GH Struijk","year":"2013","unstructured":"Struijk GH, Bouts AH, Rijkers GT, Kuin EA, ten Berge IJ, Bemelman FJ (2013) Meningococcal sepsis complicating eculizumab treatment despite prior vaccination. Am J Transplant 13:819\u2013820. \n                    https:\/\/doi.org\/10.1111\/ajt.12032","journal-title":"Am J Transplant"},{"key":"4091_CR25","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s00467-014-2990-5","volume":"30","author":"W Hayes","year":"2015","unstructured":"Hayes W, Tschumi S, Ling SC, Feber J, Kirschfink M, Licht C (2015) Eculizumab hepatotoxicity in pediatric aHUS. Pediatr Nephrol 30:775\u2013781. \n                    https:\/\/doi.org\/10.1007\/s00467-014-2990-5","journal-title":"Pediatr Nephrol"},{"key":"4091_CR26","doi-asserted-by":"publisher","unstructured":"Oruc A, Ayar Y, Vuruskan BA, Yildiz A, Aktas N, Yavuz M, Gullulu M, Dilek K, Ersoy A (2017) Hepatotoxicity associated with eculizumab in a patient with atypical hemolytic uremic syndrome. Nefrologia. \n                    https:\/\/doi.org\/10.1016\/j.nefro.2017.10.001","DOI":"10.1016\/j.nefro.2017.10.001"},{"key":"4091_CR27","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1007\/s00467-017-3642-3","volume":"32","author":"KL Wijnsma","year":"2017","unstructured":"Wijnsma KL, Schijvens AM, Rossen JWA, Kooistra-Smid A, Schreuder MF, van de Kar N (2017) Unusual severe case of hemolytic uremic syndrome due to Shiga toxin 2d-producing E. coli O80:H2. Pediatr Nephrol 32:1263\u20131268. \n                    https:\/\/doi.org\/10.1007\/s00467-017-3642-3","journal-title":"Pediatr Nephrol"},{"key":"4091_CR28","unstructured":"European Medicines Agency (2007) Soliris: EPAR- Scientific discussion"},{"key":"4091_CR29","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jim.2018.06.010","volume":"460","author":"MAV Willrich","year":"2018","unstructured":"Willrich MAV, Andreguetto BD, Sridharan M, Fervenza FC, Tostrud LJ, Ladwig PM, Rivard AM, Hetrick MD, Olson RN, Bryant SC, Snyder MR, Murray DL (2018) The impact of eculizumab on routine complement assays. J Immunol Methods 460:63\u201371. \n                    https:\/\/doi.org\/10.1016\/j.jim.2018.06.010","journal-title":"J Immunol Methods"},{"key":"4091_CR30","unstructured":"National institute for health and care excellence (2015) Eculizumab for treating atypical haemolytic uraemic syndrome"},{"key":"4091_CR31","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/qjmed\/hcv082","volume":"109","author":"NS Sheerin","year":"2016","unstructured":"Sheerin NS, Kavanagh D, Goodship TH, Johnson S (2016) A national specialized service in England for atypical haemolytic uraemic syndrome-the first year\u2019s experience. QJM 109:27\u201333. \n                    https:\/\/doi.org\/10.1093\/qjmed\/hcv082","journal-title":"QJM"},{"key":"4091_CR32","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s40620-016-0288-3","volume":"30","author":"JV Walle","year":"2017","unstructured":"Walle JV, Delmas Y, Ardissino G, Wang J, Kincaid JF, Haller H (2017) Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizumab treatment. J Nephrol 30:127\u2013134. \n                    https:\/\/doi.org\/10.1007\/s40620-016-0288-3","journal-title":"J Nephrol"},{"key":"4091_CR33","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1053\/j.seminhematol.2018.04.009","volume":"55","author":"F Fakhouri","year":"2018","unstructured":"Fakhouri F, Loirat C (2018) Anticomplement treatment in atypical and typical hemolytic uremic syndrome. Semin Hematol 55:150\u2013158. \n                    https:\/\/doi.org\/10.1053\/j.seminhematol.2018.04.009","journal-title":"Semin Hematol"},{"key":"4091_CR34","unstructured":"Food and Drug Administration (2011) Approval package for application number 125166s172"},{"key":"4091_CR35","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1080\/19420862.2015.1086049","volume":"7","author":"P Gatault","year":"2015","unstructured":"Gatault P, Brachet G, Ternant D, Degenne D, Recipon G, Barbet C, Gyan E, Gouilleux-Gruart V, Bordes C, Farrell A, Halimi JM, Watier H (2015) Therapeutic drug monitoring of eculizumab: rationale for an individualized dosing schedule. MAbs 7:1205\u20131211. \n                    https:\/\/doi.org\/10.1080\/19420862.2015.1086049","journal-title":"MAbs"},{"key":"4091_CR36","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1002\/cpt.686","volume":"102","author":"E Volokhina","year":"2017","unstructured":"Volokhina E, Wijnsma K, van der Molen R, Roeleveld N, van der Velden T, Goertz J, Sweep F, Bruggemann RJ, Wetzels J, van de Kar N, van den Heuvel L (2017) Eculizumab dosing regimen in atypical HUS: possibilities for individualized treatment. Clin Pharmacol Ther 102:671\u2013678. \n                    https:\/\/doi.org\/10.1002\/cpt.686","journal-title":"Clin Pharmacol Ther"},{"key":"4091_CR37","doi-asserted-by":"publisher","unstructured":"Ardissino G, Tel F, Sgarbanti M, Cresseri D, Giussani A, Griffini S, Grovetto E, Possenti I, Perrone M, Testa S, Paglialonga F, Messa P, Cugno M (2017) Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome: an update. Pediatr Nephrol. \n                    https:\/\/doi.org\/10.1007\/s00467-017-3813-2","DOI":"10.1007\/s00467-017-3813-2"},{"key":"4091_CR38","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.molimm.2017.05.013","volume":"89","author":"D Ricklin","year":"2017","unstructured":"Ricklin D, Barratt-Due A, Mollnes TE (2017) Complement in clinical medicine: clinical trials, case reports and therapy monitoring. Mol Immunol 89:10\u201321. \n                    https:\/\/doi.org\/10.1016\/j.molimm.2017.05.013","journal-title":"Mol Immunol"},{"key":"4091_CR39","unstructured":"European medicines agency (2011) CHMP variation assessment report type II variation"},{"key":"4091_CR40","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.clim.2015.05.018","volume":"160","author":"EB Volokhina","year":"2015","unstructured":"Volokhina EB, van de Kar NC, Bergseth G, van der Velden TJ, Westra D, Wetzels JF, van den Heuvel LP, Mollnes TE (2015) Sensitive, reliable and easy-performed laboratory monitoring of eculizumab therapy in atypical hemolytic uremic syndrome. Clin Immunol 160:237\u2013243. \n                    https:\/\/doi.org\/10.1016\/j.clim.2015.05.018","journal-title":"Clin Immunol"},{"key":"4091_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clim.2017.06.007","volume":"183","author":"B Puissant-Lubrano","year":"2017","unstructured":"Puissant-Lubrano B, Puissochet S, Congy-Jolivet N, Chauveau D, Decramer S, Garnier A, Huart A, Kamar N, Ribes D, Blancher A (2017) Alternative complement pathway hemolytic assays reveal incomplete complement blockade in patients treated with eculizumab. Clin Immunol 183:1\u20137. \n                    https:\/\/doi.org\/10.1016\/j.clim.2017.06.007","journal-title":"Clin Immunol"},{"key":"4091_CR42","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1111\/cei.12890","volume":"187","author":"C Wehling","year":"2017","unstructured":"Wehling C, Amon O, Bommer M, Hoppe B, Kentouche K, Schalk G, Weimer R, Wiesener M, Hohenstein B, Tonshoff B, Buscher R, Fehrenbach H, Gok ON, Kirschfink M (2017) Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders. Clin Exp Immunol 187:304\u2013315. \n                    https:\/\/doi.org\/10.1111\/cei.12890","journal-title":"Clin Exp Immunol"},{"key":"4091_CR43","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s00467-016-3496-0","volume":"32","author":"D Westra","year":"2017","unstructured":"Westra D, Volokhina EB, van der Molen RG, van der Velden TJ, Jeronimus-Klaasen A, Goertz J, Gracchi V, Dorresteijn EM, Bouts AH, Keijzer-Veen MG, van Wijk JA, Bakker JA, Roos A, van den Heuvel LP, van de Kar NC (2017) Serological and genetic complement alterations in infection-induced and complement-mediated hemolytic uremic syndrome. Pediatr Nephrol 32:297\u2013309. \n                    https:\/\/doi.org\/10.1007\/s00467-016-3496-0","journal-title":"Pediatr Nephrol"},{"key":"4091_CR44","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1182\/blood-2014-02-558296","volume":"124","author":"M Noris","year":"2014","unstructured":"Noris M, Galbusera M, Gastoldi S, Macor P, Banterla F, Bresin E, Tripodo C, Bettoni S, Donadelli R, Valoti E, Tedesco F, Amore A, Coppo R, Ruggenenti P, Gotti E, Remuzzi G (2014) Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood 124:1715\u20131726. \n                    https:\/\/doi.org\/10.1182\/blood-2014-02-558296","journal-title":"Blood"},{"key":"4091_CR45","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1182\/blood-2017-02-770214","volume":"130","author":"SA Merrill","year":"2017","unstructured":"Merrill SA, Brittingham ZD, Yuan X, Moliterno AR, Sperati CJ, Brodsky RA (2017) Eculizumab cessation in atypical hemolytic uremic syndrome. Blood 130:368\u2013372. \n                    https:\/\/doi.org\/10.1182\/blood-2017-02-770214","journal-title":"Blood"},{"key":"4091_CR46","doi-asserted-by":"publisher","first-page":"3637","DOI":"10.1182\/blood-2015-02-629683","volume":"125","author":"E Gavriilaki","year":"2015","unstructured":"Gavriilaki E, Yuan X, Ye Z, Ambinder AJ, Shanbhag SP, Streiff MB, Kickler TS, Moliterno AR, Sperati CJ, Brodsky RA (2015) Modified ham test for atypical hemolytic uremic syndrome. Blood 125:3637\u20133646. \n                    https:\/\/doi.org\/10.1182\/blood-2015-02-629683","journal-title":"Blood"},{"key":"4091_CR47","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1111\/jth.12764","volume":"13","author":"M Cugno","year":"2015","unstructured":"Cugno M, Tedeschi S, Ardissino G (2015) Tailored eculizumab regimen for patients with atypical hemolytic uremic syndrome: requirement for comprehensive complement analysis: comment. J Thromb Haemost 13:485\u2013486. \n                    https:\/\/doi.org\/10.1111\/jth.12764","journal-title":"J Thromb Haemost"},{"key":"4091_CR48","doi-asserted-by":"publisher","first-page":"3253","DOI":"10.1182\/blood-2014-09-600411","volume":"125","author":"R Cofiell","year":"2015","unstructured":"Cofiell R, Kukreja A, Bedard K, Yan Y, Mickle AP, Ogawa M, Bedrosian CL, Faas SJ (2015) Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS. Blood 125:3253\u20133262. \n                    https:\/\/doi.org\/10.1182\/blood-2014-09-600411","journal-title":"Blood"},{"key":"4091_CR49","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1111\/jth.12615","volume":"12","author":"M Cugno","year":"2014","unstructured":"Cugno M, Gualtierotti R, Possenti I, Testa S, Tel F, Griffini S, Grovetti E, Tedeschi S, Salardi S, Cresseri D, Messa P, Ardissino G (2014) Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome. J Thromb Haemost 12:1440\u20131448. \n                    https:\/\/doi.org\/10.1111\/jth.12615","journal-title":"J Thromb Haemost"},{"key":"4091_CR50","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1053\/j.ajkd.2015.04.010","volume":"66","author":"G Ardissino","year":"2015","unstructured":"Ardissino G, Possenti I, Tel F, Testa S, Salardi S, Ladisa V (2015) Discontinuation of eculizumab treatment in atypical hemolytic uremic syndrome: an update. Am J Kidney Dis 66:172\u2013173. \n                    https:\/\/doi.org\/10.1053\/j.ajkd.2015.04.010","journal-title":"Am J Kidney Dis"},{"key":"4091_CR51","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1053\/j.ajkd.2014.01.434","volume":"64","author":"G Ardissino","year":"2014","unstructured":"Ardissino G, Testa S, Possenti I, Tel F, Paglialonga F, Salardi S, Tedeschi S, Belingheri M, Cugno M (2014) Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases. Am J Kidney Dis 64:633\u2013637. \n                    https:\/\/doi.org\/10.1053\/j.ajkd.2014.01.434","journal-title":"Am J Kidney Dis"},{"key":"4091_CR52","doi-asserted-by":"publisher","first-page":"50","DOI":"10.2215\/cjn.06440616","volume":"12","author":"F Fakhouri","year":"2017","unstructured":"Fakhouri F, Fila M, Provot F, Delmas Y, Barbet C, Chatelet V, Rafat C, Cailliez M, Hogan J, Servais A, Karras A, Makdassi R, Louillet F, Coindre JP, Rondeau E, Loirat C, Fremeaux-Bacchi V (2017) Pathogenic variants in complement genes and risk of atypical hemolytic uremic syndrome relapse after Eculizumab discontinuation. Clin J Am Soc Nephrol 12:50\u201359. \n                    https:\/\/doi.org\/10.2215\/cjn.06440616","journal-title":"Clin J Am Soc Nephrol"},{"key":"4091_CR53","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1093\/ckj\/sfw115","volume":"10","author":"M Macia","year":"2017","unstructured":"Macia M, de Alvaro Moreno F, Dutt T, Fehrman I, Hadaya K, Gasteyger C, Heyne N (2017) Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome. Clin Kidney J 10:310\u2013319. \n                    https:\/\/doi.org\/10.1093\/ckj\/sfw115","journal-title":"Clin Kidney J"},{"key":"4091_CR54","doi-asserted-by":"publisher","unstructured":"Wijnsma KL, Duineveld C, Volokhina EB, van den Heuvel LP, van de Kar N, Wetzels JFM (2017) Safety and effectiveness of restrictive eculizumab treatment in atypical haemolytic uremic syndrome. Nephrol Dial Transplant \n                    https:\/\/doi.org\/10.1093\/ndt\/gfx196","DOI":"10.1093\/ndt\/gfx196"},{"key":"4091_CR55","doi-asserted-by":"publisher","first-page":"88","DOI":"10.2215\/Cjn.00050505","volume":"1","author":"E Bresin","year":"2006","unstructured":"Bresin E, Daina E, Noris M, Castelletti F, Stefanov R, Hill P, Goodship THJ, Remuzzi G (2006) Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance-of genetic background. Clin J Am Soc Nephrol 1:88\u201399. \n                    https:\/\/doi.org\/10.2215\/Cjn.00050505","journal-title":"Clin J Am Soc Nephrol"},{"key":"4091_CR56","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.trre.2013.07.003","volume":"27","author":"J Zuber","year":"2013","unstructured":"Zuber J, Le Quintrec M, Morris H, Fremeaux-Bacchi V, Loirat C, Legendre C (2013) Targeted strategies in the prevention and management of atypical HUS recurrence after kidney transplantation. Transplant Rev (Orlando) 27:117\u2013125. \n                    https:\/\/doi.org\/10.1016\/j.trre.2013.07.003","journal-title":"Transplant Rev (Orlando)"},{"key":"4091_CR57","doi-asserted-by":"publisher","first-page":"88","DOI":"10.2215\/CJN.00050505","volume":"1","author":"E Bresin","year":"2006","unstructured":"Bresin E, Daina E, Noris M, Castelletti F, Stefanov R, Hill P, Goodship TH, Remuzzi G, International Registry of R, Familial HT (2006) Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background. Clin J Am Soc Nephrol 1:88\u201399. \n                    https:\/\/doi.org\/10.2215\/CJN.00050505","journal-title":"Clin J Am Soc Nephrol"},{"key":"4091_CR58","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/j.1399-3046.2008.00910.x","volume":"12","author":"C Loirat","year":"2008","unstructured":"Loirat C, Fremeaux-Bacchi V (2008) Hemolytic uremic syndrome recurrence after renal transplantation. Pediatr Transplant 12:619\u2013629. \n                    https:\/\/doi.org\/10.1111\/j.1399-3046.2008.00910.x","journal-title":"Pediatr Transplant"},{"key":"4091_CR59","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1093\/ndt\/12.7.1425","volume":"12","author":"RB Miller","year":"1997","unstructured":"Miller RB, Burke BA, Schmidt WJ, Gillingham KJ, Matas AJ, Mauer M, Kashtan CE (1997) Recurrence of haemolytic-uraemic syndrome in renal transplants: a single-Centre report. Nephrol Dial Transplant 12:1425\u20131430","journal-title":"Nephrol Dial Transplant"},{"key":"4091_CR60","first-page":"842","volume":"27","author":"VP Scantlebury","year":"1995","unstructured":"Scantlebury VP, Shapiro R, McCauley J, Jordan M, Vivas C, Irish W, Tzakis A, Ellis D, Gilboa N, Starzl TE (1995) Renal transplantation under cyclosporine and FK 506 for hemolytic uremic syndrome. Transplant Proc 27:842\u2013843","journal-title":"Transplant Proc"},{"key":"4091_CR61","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1097\/01.Tp.0000085083.74065.1b","volume":"76","author":"MA Artz","year":"2003","unstructured":"Artz MA, Steenbergen EJ, Hoitsma AJ, Monnens LAH, Wetzels JFM (2003) Renal transplantation in patients with hemolytic uremic syndrome: high rate of recurrence increased incidence of acute rejections. Transplantation 76:821\u2013826. \n                    https:\/\/doi.org\/10.1097\/01.Tp.0000085083.74065.1b","journal-title":"Transplantation"},{"key":"4091_CR62","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1007\/s00467-003-1289-8","volume":"18","author":"C Loirat","year":"2003","unstructured":"Loirat C, Niaudet P (2003) The risk of recurrence of hemolytic uremic syndrome after renal transplantation in children. Pediatr Nephrol 18:1095\u20131101. \n                    https:\/\/doi.org\/10.1007\/s00467-003-1289-8","journal-title":"Pediatr Nephrol"},{"key":"4091_CR63","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1681\/ASN.2006080811","volume":"18","author":"AL Sellier-Leclerc","year":"2007","unstructured":"Sellier-Leclerc AL, Fremeaux-Bacchi V, Dragon-Durey MA, Macher MA, Niaudet P, Guest G, Boudailliez B, Bouissou F, Deschenes G, Gie S, Tsimaratos M, Fischbach M, Morin D, Nivet H, Alberti C, Loirat C, French Society of Pediatric N (2007) Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol 18:2392\u20132400. \n                    https:\/\/doi.org\/10.1681\/ASN.2006080811","journal-title":"J Am Soc Nephrol"},{"key":"4091_CR64","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.trre.2017.10.001","volume":"32","author":"N Garg","year":"2018","unstructured":"Garg N, Rennke HG, Pavlakis M, Zandi-Nejad K (2018) De novo thrombotic microangiopathy after kidney transplantation. Transplant Rev 32:58\u201368. \n                    https:\/\/doi.org\/10.1016\/j.trre.2017.10.001","journal-title":"Transplant Rev"},{"key":"4091_CR65","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1093\/ckj\/sfx053","volume":"10","author":"J Munch","year":"2017","unstructured":"Munch J, Bachmann A, Grohmann M, Mayer C, Kirschfink M, Lindner TH, Bergmann C, Halbritter J (2017) Effective immunosuppressive management with belatacept and eculizumab in post-transplant aHUS due to a homozygous deletion of CFHR1\/CFHR3 and the presence of CFH antibodies. Clin Kidney J 10:742\u2013746. \n                    https:\/\/doi.org\/10.1093\/ckj\/sfx053","journal-title":"Clin Kidney J"},{"key":"4091_CR66","doi-asserted-by":"publisher","first-page":"3337","DOI":"10.1111\/j.1600-6143.2012.04252.x","volume":"12","author":"J Zuber","year":"2012","unstructured":"Zuber J, Le Quintrec M, Krid S, Bertoye C, Gueutin V, Lahoche A, Heyne N, Ardissino G, Chatelet V, Noel LH, Hourmant M, Niaudet P, Fremeaux-Bacchi V, Rondeau E, Legendre C, Loirat C (2012) Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. Am J Transplant 12:3337\u20133354. \n                    https:\/\/doi.org\/10.1111\/j.1600-6143.2012.04252.x","journal-title":"Am J Transplant"},{"key":"4091_CR67","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/tri.12440","volume":"28","author":"A Parikova","year":"2015","unstructured":"Parikova A, Fronek JP, Viklicky O (2015) Living-donor kidney transplantation for atypical haemolytic uremic syndrome with pre-emptive eculizumab use. Transpl Int 28:366\u2013369. \n                    https:\/\/doi.org\/10.1111\/tri.12440","journal-title":"Transpl Int"},{"key":"4091_CR68","doi-asserted-by":"publisher","first-page":"200","DOI":"10.5414\/cn108808","volume":"86","author":"A Riddell","year":"2016","unstructured":"Riddell A, Goodship T, Bingham C (2016) Prevention of recurrence of atypical hemolytic uremic syndrome post renal transplant with the use of higher-dose eculizumab. Clin Nephrol 86:200\u2013202. \n                    https:\/\/doi.org\/10.5414\/cn108808","journal-title":"Clin Nephrol"},{"key":"4091_CR69","doi-asserted-by":"publisher","first-page":"E185","DOI":"10.1111\/petr.12290","volume":"18","author":"D Ranch","year":"2014","unstructured":"Ranch D, Crowther B, Arar M, Assanasen C (2014) Prophylactic eculizumab for kidney transplantation in a child with atypical hemolytic uremic syndrome due to complement factor H mutation. Pediatr Transplant 18:E185\u2013E189. \n                    https:\/\/doi.org\/10.1111\/petr.12290","journal-title":"Pediatr Transplant"},{"key":"4091_CR70","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0188155","volume":"12","author":"LGM Andrade de","year":"2017","unstructured":"de Andrade LGM, Contti MM, Nga HS, Bravin AM, Takase HM, Viero RM, da Silva TN, Chagas KN, Palma LMP (2017) Long-term outcomes of the atypical hemolytic uremic syndrome after kidney transplantation treated with eculizumab as first choice. PLoS One 12:e0188155. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0188155","journal-title":"PLoS One"},{"key":"4091_CR71","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1097\/tp.0000000000000200","volume":"98","author":"D Matar","year":"2014","unstructured":"Matar D, Naqvi F, Racusen LC, Carter-Monroe N, Montgomery RA, Alachkar N (2014) Atypical hemolytic uremic syndrome recurrence after kidney transplantation. Transplantation 98:1205\u20131212. \n                    https:\/\/doi.org\/10.1097\/tp.0000000000000200","journal-title":"Transplantation"},{"key":"4091_CR72","doi-asserted-by":"publisher","first-page":"714","DOI":"10.12659\/AOT.894665","volume":"20","author":"U Kasapoglu","year":"2015","unstructured":"Kasapoglu U, Ruhi C, Tugcu M, Boynuegri B, Titiz I, Hancer VS, Apaydin S (2015) Prophylactic eculizumab use in kidney transplantation: a review of the literature and report of a case with atypical hemolytic uremic syndrome. Ann Transplant 20:714\u2013719","journal-title":"Ann Transplant"},{"key":"4091_CR73","doi-asserted-by":"publisher","first-page":"2924","DOI":"10.1097\/tp.0000000000001909","volume":"101","author":"C Levi","year":"2017","unstructured":"Levi C, Fremeaux-Bacchi V, Zuber J, Rabant M, Devriese M, Snanoudj R, Scemla A, Amrouche L, Mejean A, Legendre C, Sberro-Soussan R (2017) Midterm outcomes of 12 renal transplant recipients treated with eculizumab to prevent atypical hemolytic syndrome recurrence. Transplantation 101:2924\u20132930. \n                    https:\/\/doi.org\/10.1097\/tp.0000000000001909","journal-title":"Transplantation"},{"key":"4091_CR74","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/nep.12937","volume":"22","author":"AR Krishnan","year":"2017","unstructured":"Krishnan AR, Siva B, Chakera A, Wong G, Wong D, Lim WH (2017) Absence of thrombocytopaenia and\/or microangiopathic haemolytic anaemia does not reliably exclude recurrence of atypical haemolytic uraemic syndrome after kidney transplantation. Nephrology 22:28\u201331. \n                    https:\/\/doi.org\/10.1111\/nep.12937","journal-title":"Nephrology"},{"key":"4091_CR75","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1111\/j.1600-6143.2005.01184.x","volume":"6","author":"O Oyen","year":"2006","unstructured":"Oyen O, Strom EH, Midtvedt K, Bentdal O, Hartmann A, Bergan S, Pfeffer P, Brekke IB (2006) Calcineurin inhibitor-free immunosuppression in renal allograft recipients with thrombotic microangiopathy\/hemolytic uremic syndrome. Am J Transplant 6:412\u2013418. \n                    https:\/\/doi.org\/10.1111\/j.1600-6143.2005.01184.x","journal-title":"Am J Transplant"},{"key":"4091_CR76","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1053\/j.ajkd.2017.06.024","volume":"70","author":"C Duineveld","year":"2017","unstructured":"Duineveld C, Verhave JC, Berger SP, van de Kar N, Wetzels JFM (2017) Living donor kidney transplantation in atypical hemolytic uremic syndrome: a case series. Am J Kidney Dis 70:770\u2013777. \n                    https:\/\/doi.org\/10.1053\/j.ajkd.2017.06.024","journal-title":"Am J Kidney Dis"},{"key":"4091_CR77","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1111\/tri.13022","volume":"30","author":"CM Legendre","year":"2017","unstructured":"Legendre CM, Campistol JM, Feldkamp T, Remuzzi G, Kincaid JF, Lommele A, Wang J, Weekers LE, Sheerin NS (2017) Outcomes of patients with atypical haemolytic uraemic syndrome with native and transplanted kidneys treated with eculizumab: a pooled post hoc analysis. Transpl Int 30:1275\u20131283. \n                    https:\/\/doi.org\/10.1111\/tri.13022","journal-title":"Transpl Int"},{"key":"4091_CR78","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1111\/imj.12864","volume":"45","author":"A Mallett","year":"2015","unstructured":"Mallett A, Hughes P, Szer J, Tuckfield A, Van Eps C, Cambell SB, Hawley C, Burke J, Kausman J, Hewitt I, Parnham A, Ford S, Isbel N (2015) Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: the experience of the Australian compassionate access cohort. Intern Med J 45:1054\u20131065. \n                    https:\/\/doi.org\/10.1111\/imj.12864","journal-title":"Intern Med J"},{"key":"4091_CR79","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1056\/NEJMc0808527","volume":"360","author":"J Nurnberger","year":"2009","unstructured":"Nurnberger J, Philipp T, Witzke O, Opazo Saez A, Vester U, Baba HA, Kribben A, Zimmerhackl LB, Janecke AR, Nagel M, Kirschfink M (2009) Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med 360:542\u2013544. \n                    https:\/\/doi.org\/10.1056\/NEJMc0808527","journal-title":"N Engl J Med"},{"key":"4091_CR80","doi-asserted-by":"publisher","first-page":"E177","DOI":"10.1111\/petr.12151","volume":"17","author":"S Sinibaldi","year":"2013","unstructured":"Sinibaldi S, Guzzo I, Piras R, Bresin E, Emma F, Dello Strologo L (2013) Post-transplant recurrence of atypical hemolytic uremic syndrome in a patient with thrombomodulin mutation. Pediatr Transplant 17:E177\u2013E181. \n                    https:\/\/doi.org\/10.1111\/petr.12151","journal-title":"Pediatr Transplant"},{"key":"4091_CR81","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1097\/TP.0b013e3181ccd80d","volume":"89","author":"CF Larrea","year":"2010","unstructured":"Larrea CF, Cofan F, Oppenheimer F, Campistol JM, Escolar G, Lozano M (2010) Efficacy of eculizumab in the treatment of recurrent atypical hemolytic-uremic syndrome after renal transplantation. Transplantation 89:903\u2013904. \n                    https:\/\/doi.org\/10.1097\/TP.0b013e3181ccd80d","journal-title":"Transplantation"},{"key":"4091_CR82","doi-asserted-by":"publisher","first-page":"e93","DOI":"10.1111\/j.1432-2277.2012.01497.x","volume":"25","author":"N Alachkar","year":"2012","unstructured":"Alachkar N, Bagnasco SM, Montgomery RA (2012) Eculizumab for the treatment of two recurrences of atypical hemolytic uremic syndrome in a kidney allograft. Transpl Int 25:e93\u2013e95. \n                    https:\/\/doi.org\/10.1111\/j.1432-2277.2012.01497.x","journal-title":"Transpl Int"},{"key":"4091_CR83","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1182\/blood.V114.22.2421.2421","volume":"114","author":"DJ Legault","year":"2009","unstructured":"Legault DJ, Boelkins MR (2009) Successful treatment of aHUS recurrence and arrest of plasma exchange resistant TMA post-renal transplantation with the terminal complement inhibitor Eculizumab. Blood 114:2421","journal-title":"Blood"},{"key":"4091_CR84","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s40620-016-0373-7","volume":"31","author":"NA Zwang","year":"2018","unstructured":"Zwang NA, Ho B, Kanwar YS, Lewis B, Cusick M, Friedewald JJ, Gallon L (2018) A case of atypical hemolytic uremic syndrome in a second renal transplant. J Nephrol 31:165\u2013172. \n                    https:\/\/doi.org\/10.1007\/s40620-016-0373-7","journal-title":"J Nephrol"},{"key":"4091_CR85","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1016\/j.transproceed.2015.08.004","volume":"47","author":"Z Iqbal","year":"2015","unstructured":"Iqbal Z, Wood K, Carter V, Goodship TH, Brown AL, Sheerin NS (2015) Thrombotic Microangiopathy as a cause of chronic kidney transplant dysfunction: case report demonstrating successful treatment with eculizumab. Transplant Proceed 47:2258\u20132261. \n                    https:\/\/doi.org\/10.1016\/j.transproceed.2015.08.004","journal-title":"Transplant Proceed"},{"key":"4091_CR86","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/nep.12936","volume":"22","author":"L Shochet","year":"2017","unstructured":"Shochet L, Kanellis J, Simpson I, Ta J, Mulley W (2017) De novo thrombotic microangiopathy following simultaneous pancreas and kidney transplantation managed with eculizumab. Nephrology 22:23\u201327. \n                    https:\/\/doi.org\/10.1111\/nep.12936","journal-title":"Nephrology"},{"key":"4091_CR87","doi-asserted-by":"publisher","first-page":"e1110","DOI":"10.1097\/MJT.0000000000000133","volume":"23","author":"H Salameh","year":"2016","unstructured":"Salameh H, Abu Omar M, Alhariri A, Kisra S, Qasem A, Abdulhak AB (2016) Adult Post-Kidney Transplant Familial Atypical Hemolytic Uremic Syndrome Successfully Treated With Eculizumab: A Case Report and Literature Review. Am J Ther 23:e1110\u2013e1115","journal-title":"Am J Ther"},{"key":"4091_CR88","doi-asserted-by":"crossref","unstructured":"Broeders EN, Stordeur P, Rorive S, Dahan K (2014) A 'silent', new polymorphism of factor H and apparent de novo atypical haemolytic uraemic syndrome after kidney transplantation. BMJ Case Rep:2014","DOI":"10.1136\/bcr-2014-207630"},{"key":"4091_CR89","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s00467-010-1708-6","volume":"26","author":"SI Al-Akash","year":"2011","unstructured":"Al-Akash SI, Almond PS, Savell VH Jr, Gharaybeh SI, Hogue C (2011) Eculizumab induces long-term remission in recurrent post-transplant HUS associated with C3 gene mutation. Pediatr Nephrol 26:613\u2013619","journal-title":"Pediatr Nephrol"},{"key":"4091_CR90","doi-asserted-by":"publisher","unstructured":"Garlo K, Dressel D, Savic M, Vella J (2015) Successful eculizumab treatment of recurrent postpartum atypical hemolytic uremic syndrome after kidney transplantation. Clin Nephrol Case Stud 3:8\u201313. \n                    https:\/\/doi.org\/10.5414\/CNCS108491","DOI":"10.5414\/CNCS108491"},{"key":"4091_CR91","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1016\/j.transproceed.2011.02.064","volume":"43","author":"S Chandran","year":"2011","unstructured":"Chandran S, Baxter-Lowe L, Olson JL, Tomlanovich SJ, Webber A (2011) Eculizumab for the Treatment of De Novo Thrombotic Microangiopathy Post Simultaneous Pancreas-Kidney Transplantation-A Case Report. Transplant Proc 43:2097\u20132101","journal-title":"Transplant Proc"},{"key":"4091_CR92","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.nefro.2016.02.003","volume":"36","author":"FJ Juega-Marino","year":"2016","unstructured":"Juega-Marino FJ, Sala N, Lopez D, Canas L, Bonet J, Lauzurica R (2016) Late onset of de novo atypical hemolytic-uremic syndrome presented on a simultaneous pancreas and kidney transplant recipient successfully treated with eculizumab. Nefrologia 36:328\u2013329","journal-title":"Nefrologia"},{"key":"4091_CR93","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1159\/000337954","volume":"35","author":"KS Hodgkins","year":"2012","unstructured":"Hodgkins KS, Bobrowski AE, Lane JC, Langman CB (2012) Clinical Grand Rounds: Atypical Hemolytic Uremic Syndrome. Am J Nephrol 35:394\u2013400","journal-title":"Am J Nephrol"},{"key":"4091_CR94","doi-asserted-by":"publisher","first-page":"e74","DOI":"10.1097\/01.TP.0000435705.63428.1f","volume":"96","author":"S Reuter","year":"2013","unstructured":"Reuter S, Heitplatz B, Pavenstadt H, Suwelack B (2013) Successful long-term treatment of TMA with eculizumab in a transplanted patient with atypical hemolytic uremic syndrome due to MCP mutation. Transplantation 96:e74\u2013e76","journal-title":"Transplantation"},{"key":"4091_CR95","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.transproceed.2016.10.013","volume":"49","author":"T Yamamoto","year":"2017","unstructured":"Yamamoto T, Watarai Y, Futamura K, Okada M, Tsujita M, Hiramitsu T, Goto N, Narumi S, Takeda A, Kobayashi T (2017) Efficacy of Eculizumab Therapy for Atypical Hemolytic Uremic Syndrome Recurrence and Antibody-Mediated Rejection Progress After Renal Transplantation With Preformed Donor-Specific Antibodies: Case Report. Transplant Proc 49:159\u2013162","journal-title":"Transplant Proc"},{"key":"4091_CR96","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/j.1432-2277.2010.01192.x","volume":"24","author":"N Heyne","year":"2011","unstructured":"Heyne N, Weitz M, Guthoff M, Alscher M, H-u H, K\u00f6nigsrainer A, Nadalin S (2011) Terminal complement blockade by eculizumab effectively reverses recurrent atypical hemolytic uremic syndrome after kidney transplantation. Transpl Int 24:35","journal-title":"Transpl Int"},{"key":"4091_CR97","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/nrneph.2012.214","volume":"8","author":"J Zuber","year":"2012","unstructured":"Zuber J, Fakhouri F, Roumenina LT, Loirat C, Fremeaux-Bacchi V (2012) Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 8:643\u2013657. \n                    https:\/\/doi.org\/10.1038\/nrneph.2012.214","journal-title":"Nat Rev Nephrol"},{"key":"4091_CR98","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1159\/000468528","volume":"136","author":"SM Manani","year":"2017","unstructured":"Manani SM, Virzi GM, Giuliani A, Clementi A, Brocca A, Dissegna D, Martino F, d'Amore ESG, Ronco C (2017) Hemolytic uremic syndrome and kidney transplantation: a case series and review of the literature. Nephron 136:245\u2013253. \n                    https:\/\/doi.org\/10.1159\/000468528","journal-title":"Nephron"},{"key":"4091_CR99","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1111\/j.1600-6143.2012.04051.x","volume":"12","author":"S Krid","year":"2012","unstructured":"Krid S, Roumenina LT, Beury D, Charbit M, Boyer O, Fremeaux-Bacchi V, Niaudet P (2012) Renal transplantation under prophylactic eculizumab in atypical hemolytic uremic syndrome with CFH\/CFHR1 hybrid protein. Am J Transplant 12:1938\u20131944. \n                    https:\/\/doi.org\/10.1111\/j.1600-6143.2012.04051.x","journal-title":"Am J Transplant"},{"key":"4091_CR100","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1007\/s00467-011-1879-9","volume":"26","author":"M Weitz","year":"2011","unstructured":"Weitz M, Amon O, Bassler D, Koenigsrainer A, Nadalin S (2011) Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome. Pediatr Nephrol 26:1325\u20131329. \n                    https:\/\/doi.org\/10.1007\/s00467-011-1879-9","journal-title":"Pediatr Nephrol"},{"key":"4091_CR101","doi-asserted-by":"publisher","first-page":"2644","DOI":"10.1111\/j.1600-6143.2009.02817.x","volume":"9","author":"V Chatelet","year":"2009","unstructured":"Chatelet V, Fremeaux-Bacchi V, Lobbedez T, Ficheux M, Hurault de Ligny B (2009) Safety and long-term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome. Am J Transplant 9:2644\u20132645. \n                    https:\/\/doi.org\/10.1111\/j.1600-6143.2009.02817.x","journal-title":"Am J Transplant"},{"key":"4091_CR102","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1056\/NEJMoa1311084","volume":"370","author":"JI Nishimura","year":"2014","unstructured":"Nishimura JI, Yamamoto M, Hayashi S, Ohyashiki K, Ando K, Brodsky AL, Noji H, Kitamura K, Eto T, Takahashi T, Masuko M, Matsumoto T, Wano Y, Shichishima T, Shibayama H, Hase M, Li L, Johnson K, Lazarowski A, Tamburini P, Inazawa J, Kinoshita T, Kanakura Y (2014) Genetic variants in C5 and poor response to eculizumab. N Engl J Med 370:632\u2013639","journal-title":"N Engl J Med"},{"key":"4091_CR103","doi-asserted-by":"publisher","first-page":"i115","DOI":"10.1093\/ndt\/gfw353","volume":"32","author":"JA Brand van den","year":"2017","unstructured":"van den Brand JA, Verhave JC, Adang EM, Wetzels JF (2017) Cost-effectiveness of eculizumab treatment after kidney transplantation in patients with atypical haemolytic uraemic syndrome. Nephrol Dial Transplant 32:i115\u2013i122. \n                    https:\/\/doi.org\/10.1093\/ndt\/gfw353","journal-title":"Nephrol Dial Transplant"}],"updated-by":[{"DOI":"10.1007\/s00467-018-4186-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,1,15]],"date-time":"2019-01-15T00:00:00Z","timestamp":1547510400000}}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00467-018-4091-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-018-4091-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-018-4091-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,5]],"date-time":"2019-11-05T19:11:54Z","timestamp":1572981114000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00467-018-4091-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,6]]},"references-count":103,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["4091"],"URL":"https:\/\/doi.org\/10.1007\/s00467-018-4091-3","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,6]]},"assertion":[{"value":"18 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2019","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original version of this article unfortunately contained two mistakes. The presentation of Table 1 and Fig. 1 was incorrect. The corrected versions are given below.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. van de Kar and Prof. dr. Wetzels are members of the Alexion Scientific Advisory Board of aHUS and received consultation and speakers\u2019 fees. The authors declare that they have no other relevant financial interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}